At the **ECCO**, the annual conference of the European Crohn’s Colitis organisation, in Amsterdam, March 16 – 19, 2016, Wintgens et al reported about **first results with QuantOn Cal®**: 

**Analytical performance of a new iPhone-based patient monitoring system comparable to ELISA for measuring fecal calprotectin in IBD patients**

AUTHORS: Wintgens, Karl Florian; Wulandari, A; Dignass, Axel; Hartmann, Franz; Stein, Jürgen

**Abstract:** Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder presenting with phases of active inflammation, remission and relapse. Fecal calprotectin (fcalpro) measurement has become established for the monitoring of inflammation activity. Periodical assessment of fcalpro levels has been demonstrated to be an important non-invasive indicator of treatment efficacy and predictor of relapse. However, until now, fcalpro determination required patients to send stool samples in for laboratory analysis, resulting in a long delay between sample collection and final test results. We developed a simple home-based calprotectin test system called QuantOnCal to allow patients to regularly monitor their own inflammatory status by testing fcalpro levels in the comfort of their own home.

**Conclusion:** QuantOnCal® is a new, complete and validated test system which allows the IBD patient to monitor and follow his inflammatory status by measuring the IBD biomarker, faecal calprotectin, using his/her own smartphone. The performance of the QuantOnCal® test system was shown to be comparable to the professional, ELISA-based method.